Emergent Biosolutions (EBS)
(Delayed Data from NYSE)
$6.99 USD
+0.09 (1.30%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $6.99 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
Price, Consensus and EPS Surprise
EBS 6.99 +0.09(1.30%)
Will EBS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for EBS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EBS
Should Invesco FTSE RAFI US 1500 Small-Mid ETF (PRFZ) Be on Your Investing Radar?
EBS Stock Rises on FDA Nod for ACAM2000 in Mpox Indication
EBS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zacks Investment Ideas feature highlights: Virax Biolabs Group, GeoVax Labs, Applied DNA Sciences and Emergent BioSolutions
WHO Declares Monkeypox Public Emergency: 5 Mpox Stocks to Watch
Repligen (RGEN) Q2 Earnings Meet Estimates
Other News for EBS
Emergent BioSolutions falls -8.4%
Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation
Emergent BioSolutions to settle securities class action litigation for $40M
Emergent Bio to pay $40M to settle class action lawsuit
Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga? Treatment for Ebola